StreetInsider.com News Articles

Form SCHEDULE 13G INOVIO PHARMACEUTICALS, Filed by: RA CAPITAL MANAGEMENT, L.P.

Fri, 07 Aug 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260807/26891186.html

Form SCHEDULE 13G INOVIO PHARMACEUTICALS, Filed by: RA CAPITAL MANAGEMENT, L.P.

Fri, 07 Aug 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260807/26891186.html

Form SCHEDULE 13G/A INOVIO PHARMACEUTICALS, Filed by: FMR LLC

Thu, 06 Aug 2026 10:32:00 -0400

si-local-file:///var/storage/secattach/20260806/26881246.html

Form SCHEDULE 13G/A INOVIO PHARMACEUTICALS, Filed by: FMR LLC

Thu, 06 Aug 2026 10:32:00 -0400

si-local-file:///var/storage/secattach/20260806/26881246.html

INOVIO to Report Second Quarter Financial Results on August 12, 2026

Tue, 04 Aug 2026 16:05:00 -0400

PLYMOUTH MEETING, Pa., Aug. 4, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that its second quarter 2026 financial results will be released after the market close on August 12th, 2026. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss the financial results and provide a general business update.

INOVIO to Report Second Quarter Financial Results on August 12, 2026

Tue, 04 Aug 2026 16:05:00 -0400

INOVIO to Report Second Quarter Financial Results on August 12, 2026

Tue, 04 Aug 2026 16:05:00 -0400

INOVIO to Report Second Quarter Financial Results on August 12, 2026

Tue, 04 Aug 2026 16:05:00 -0400

Inovio Pharmaceuticals (INO) PT Lowered to $4 at Piper Sandler

Mon, 03 Aug 2026 08:14:58 -0400

Piper Sandler analyst Edward Tenthoff lowered the price target on Inovio Pharmaceuticals (NASDAQ: INO) to $4.00 (from $6.00) while maintaining a Overweight rating.

Form SCHEDULE 13G INOVIO PHARMACEUTICALS, Filed by: VANGUARD CAPITAL MANAGEMENT LLC

Fri, 31 Jul 2026 10:20:00 -0400

si-local-file:///var/storage/secattach/20260731/26848209.html

Form SCHEDULE 13G INOVIO PHARMACEUTICALS, Filed by: VANGUARD CAPITAL MANAGEMENT LLC

Fri, 31 Jul 2026 10:20:00 -0400

si-local-file:///var/storage/secattach/20260731/26848209.html

Form 8-K INOVIO PHARMACEUTICALS, For: Jul 29

Fri, 31 Jul 2026 07:23:00 -0400

si-local-file:///var/storage/secattach/20260731/26846772.html

Form 8-K INOVIO PHARMACEUTICALS, For: Jul 29

Fri, 31 Jul 2026 07:23:00 -0400

si-local-file:///var/storage/secattach/20260731/26846772.html

Form 424B5 INOVIO PHARMACEUTICALS,

Thu, 30 Jul 2026 17:27:00 -0400

si-local-file:///var/storage/secattach/20260730/26844971.html

Form 424B5 INOVIO PHARMACEUTICALS,

Thu, 30 Jul 2026 17:27:00 -0400

si-local-file:///var/storage/secattach/20260730/26844971.html

Inovio prices $20 million public offering at $0.95 per share

Wed, 29 Jul 2026 20:54:26 -0400

Inovio Pharmaceuticals (Nasdaq: INO) announced the pricing of an underwritten public offering of 21,052,632 shares of common stock along with accompanying warrants to purchase up to 42,105,264 shares, at a combined public offering price of $0.95 per share and accompanying warrant.

The warrants carry an exercise price of $1.10 per share, with each unit entitling the holder to purchase two shares of common stock. Gross proceeds are expected to be approximately $20.0 million, before deducting underwriting discounts, commissions, and offering expenses, and excluding any exercise of the warrants or the underwriter's option.

Inovio also granted the underwriter a 30-day option to purchase

Inovio prices $20 million public offering at $0.95 per share

Wed, 29 Jul 2026 20:54:26 -0400

Inovio also granted the underwriter a 30-day option to purchase

Inovio prices $20 million public offering at $0.95 per share

Wed, 29 Jul 2026 20:54:26 -0400

Inovio also granted the underwriter a 30-day option to purchase

Inovio prices $20 million public offering at $0.95 per share

Wed, 29 Jul 2026 20:54:26 -0400

Inovio also granted the underwriter a 30-day option to purchase

INOVIO Announces Pricing of $20.0 Million Public Offering